Amarin Says FDA Changed Rules To Deny Market Exclusivity
The U.S. Food and Drug Administration improperly reversed course on how it defined an active ingredient when it denied market exclusivity to Amarin Pharmaceuticals Ireland Ltd.'s drug Vascepa, the company argued...To view the full article, register now.
Already a subscriber? Click here to view full article